Topics

FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder

07:08 EST 25 Nov 2019 | Pharmaceutical Business Review

Breakthrough Therapy Designation establishes FDA’s organizational commitment to promoting an efficient development program for psilocybin in MDD. The designation of psilocybin as a Breakthrough Therapy for MDD acknowledges

The post FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder appeared first on Pharmaceutical Business review.

Original Article: FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder

NEXT ARTICLE

More From BioPortfolio on "FDA grants breakthrough therapy designation to Usona Institute’s psilocybin for major depressive disorder"

Quick Search

Relevant Topic

Drug Approvals
In order to become availible to pateints, drugs need to undergo a number of phases of clinical trials to test their efficacy and safty and to then be authorised by the drug approval organistion in each respective country. This is the FDA in the USA and N...